Fresenius Medical Care AG
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fresenius Medical Care AG & Co. KGaA Fresenius Medical Care AG & Co. KGaA operates as the world's leading provider of products and services for individuals with chronic kidney diseases, including end-stage renal disease, through a global network of approximately 3,700 dialysis clinics serving more than 299,000 patients and around 40 production sites worldwide. The company offers a comprehensive portfolio of dialysis products and services, including dialysis machines such as the 2008T BlueStar system, dialyzers like Optiflux, reverse osmosis water treatment systems, related disposables, renal pharmaceuticals for treating anemia and mineral bone disorders, peritoneal dialysis solutions including Liberty Select and CLiC systems, acute kidney injury therapies such as continuous renal replacement therapy, home hemodialysis and peritoneal dialysis programs, vascular access management, and clinical laboratory and diagnostic testing services. Headquartered in Bad Homburg v. d. Höhe, Germany, with North American headquarters in Waltham, Massachusetts, Asia-Pacific headquarters in Hong Kong, and Latin America headquarters in Rio de Janeiro, Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and U.S.-based National Medical Care, and maintains significant operations across North America, Europe, Asia-Pacific, and Latin America targeting dialysis clinics, hospitals, intensive care units, and patients requiring renal care. Recent developments include the ongoing FME Reignite strategy and FME25+ transformation program, which delivered EUR 47 million in additional benefits during the third quarter of 2025; an increased ownership stake in value-based care provider Interwell Health through a EUR 312 million investment; integration of Fresenius Health Partners, InterWell Health, and Cricket Health to manage care for 270,000 kidney disease patients; the prior acquisition of NxStage Medical, anticipated to enhance earnings; and portfolio optimization transactions in 2024 and 2025 as part of strategic realignments.
Company News
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?
3 Cheap International Stocks to Buy
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026